An Amphipathic Motif at the Transmembrane-cytoplasmic Junction Prevents Autonomous Activation of the Thrombopoietin Receptor

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2005 Oct 27

PMID 16249382

Citations 61

Authors

Judith Staerk

Catherine Lacout

Takeshi Sato

Steven O Smith

William Vainchenker

Stefan N Constantinescu

Affiliations

Soon will be listed here.

Abstract

Ligand binding to the thrombopoietin receptor (TpoR) is thought to impose a dimeric receptor conformation(s) leading to hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Unlike other cytokine receptors, such as the erythropoietin receptor, TpoR contains an amphipathic KWQFP motif at the junction between the transmembrane (TM) and cytoplasmic domains. We show here that a mutant TpoR (delta5TpoR), where this sequence was deleted, is constitutively active. In the absence of ligand, delta5TpoR activates Jak2, Tyk2, STAT5, and mitogen-activated protein (MAP) kinase, but does not appear to induce STAT3 phosphorylation. Delta5TpoR induces hematopoietic myeloid differentiation in the absence of Tpo. In the presence of Tpo, the delta5TpoR mutant appears to enhance erythroid differentiation when compared with the Tpo-activated wild-type TpoR. Strikingly, individual substitution of K507 or W508 to alanine also induces constitutive TpoR activation, indicating that the K and W residues within the amphipathic KWQFP motif are crucial for maintaining the unliganded receptor inactive. These residues may be targets for activating mutations in humans. Such a motif may exist in other receptors to prevent ligand-independent activation and to allow signaling via multiple flexible interfaces.

Citing Articles

A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.

Hussain M, Das S, Kulkarni M, Laha S Cell Oncol (Dordr). 2024; 47(5):1607-1626.

PMID: 39283476 DOI: 10.1007/s13402-024-00988-w.

Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin.

Sarson-Lawrence K, Hardy J, Iaria J, Stockwell D, Behrens K, Saiyed T Nat Commun. 2024; 15(1):1135.

PMID: 38326297 PMC: 10850085. DOI: 10.1038/s41467-024-45356-2.

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.

Defour J, Leroy E, Dass S, Balligand T, Levy G, Brett I Elife. 2023; 12.

PMID: 37338955 PMC: 10313314. DOI: 10.7554/eLife.81521.

Effects of calreticulin mutations on cell transformation and immunity.

Desikan H, Kaur A, Pogozheva I, Raghavan M J Cell Mol Med. 2023; 27(8):1032-1044.

PMID: 36916035 PMC: 10098294. DOI: 10.1111/jcmm.17713.

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Lewandowski K, Kandula Z, Gniot M, Paczkowska E, Nawrocka P, Wojtaszewska M Ann Hematol. 2022; 101(12):2665-2677.

PMID: 36266510 PMC: 9646550. DOI: 10.1007/s00277-022-05001-8.

References

Huang L, Constantinescu S, Lodish H . The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2002; 8(6):1327-38. DOI: 10.1016/s1097-2765(01)00401-4. View

Liu W, Crocker E, Constantinescu S, Smith S . Helix packing and orientation in the transmembrane dimer of gp55-P of the spleen focus forming virus. Biophys J. 2005; 89(2):1194-202. PMC: 1366604. DOI: 10.1529/biophysj.104.057844. View

Challier C, Cocault L, Berthier R, Binart N, Dusanter-Fourt I, Uzan G . The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells. Blood. 2002; 100(6):2063-70. View

Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F . Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002; 100(10):3495-503. DOI: 10.1182/blood-2002-04-1133. View

Seubert N, Royer Y, Staerk J, Kubatzky K, Moucadel V, Krishnakumar S . Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003; 12(5):1239-50. DOI: 10.1016/s1097-2765(03)00389-7. View

Storz P, Doppler H, Groner B, Pfizenmaier K, Muller G . A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression. Anal Biochem. 1999; 276(1):97-104. DOI: 10.1006/abio.1999.4345. View

Eyckerman S, Waelput W, Verhee A, Broekaert D, Vandekerckhove J, Tavernier J . Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line. Eur Cytokine Netw. 1999; 10(4):549-56. View

Richard R, Wood B, Zeng H, Jin L, Papayannopoulou T, Blau C . Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood. 2000; 95(2):430-6. View

Liu X, Constantinescu S, Sun Y, Bogan J, Hirsch D, Weinberg R . Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem. 2000; 280(1):20-8. DOI: 10.1006/abio.2000.4478. View

10.

Constantinescu S, Huang L, Nam H, Lodish H . The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell. 2001; 7(2):377-85. DOI: 10.1016/s1097-2765(01)00185-x. View

11.

Constantinescu S, Keren T, Socolovsky M, Nam H, Henis Y, Lodish H . Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001; 98(8):4379-84. PMC: 31843. DOI: 10.1073/pnas.081069198. View

12.

Millot G, Vainchenker W, Dumenil D, Svinarchuk F . Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. Cell Signal. 2003; 16(3):355-63. DOI: 10.1016/j.cellsig.2003.08.010. View

13.

Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A . Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004; 103(11):4198-200. DOI: 10.1182/blood-2003-10-3471. View

14.

van de Geijn G, Gits J, Aarts L, Heijmans-Antonissen C, Touw I . G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood. 2004; 104(3):667-74. DOI: 10.1182/blood-2003-08-2913. View

15.

Palacios R, Steinmetz M . Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985; 41(3):727-34. DOI: 10.1016/s0092-8674(85)80053-2. View

16.

Hudziak R, Schlessinger J, Ullrich A . Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987; 84(20):7159-63. PMC: 299249. DOI: 10.1073/pnas.84.20.7159. View

17.

MAGUIRE Jr H, Greene M . The neu (c-erbB-2) oncogene. Semin Oncol. 1989; 16(2):148-55. View

18.

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

19.

Yoshimura A, Longmore G, Lodish H . Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 1990; 348(6302):647-9. DOI: 10.1038/348647a0. View

20.

Souyri M, Vigon I, Penciolelli J, Heard J, Tambourin P, Wendling F . A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990; 63(6):1137-47. DOI: 10.1016/0092-8674(90)90410-g. View